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Background: Betacellulin (BTC), a member of the epidermal growth factor (EGF) family, binds and activates ErbB1
and ErbB4 homodimers. BTC was expressed in tumors and involved in tumor growth progression. CXCL8
(interleukin-8) was involved in tumor cell proliferation via the transactivation of the epidermal growth factor
receptor (EGFR).
Materials and methods: The present study was designed to investigate the possible interrelation between BTC
and CXCL8 in human lung cancer cells (A549) and demonstrated the mechanisms of intracellular signals in the
regulation of both functions. Bio-behaviors of A549 were assessed using Cell-IQ Alive Image Monitoring System.
Results: We found that BTC significantly increased the production of CXCL8 through the activation of the EGFR-PI3K/
Akt-Erk signal pathway. BTC induced the resistance of human lung cancer cells to TNF-α/CHX-induced apoptosis.
Treatments with PI3K inhibitors, Erk1/2 inhibitor, or Erlotinib significantly inhibited BTC-induced CXCL8 production and
cell proliferation and movement.
Conclusion: Our data indicated that CXCL8 production from lung cancer cells could be initiated by an autocrine
mechanism or external sources of BTC through the EGFR–PI3K–Akt–Erk pathway to the formation of inflammatory
microenvironment. BTC may act as a potential target to monitor and improve the development of lung cancer
inflammation.
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The epidermal growth factor receptor (EGFR) consists of
an extracellular ligand-binding domain, a transmembrane
domain and an intracellular tail with an ATP-binding site,
tyrosine kinase activity, and capability of autophosphoryl-
ation [1,2]. EGFR has been found to contribute the lung
development [3] and multiplicity of cancer-related signal
transduction pathways like cellular proliferation, adhesion,
migration, neoangiogenesis, and apoptosis inhibition [4].
EGFR is also responsible for the sensitivity of human non-
small cell lung cancer (NSCLC) cells to therapies and
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unless otherwise stated.bind with EGFR, such as EGF, transforming growth
factor-α (TGF-α), heparin-binding EGF-like growth factor
(HB-EGF), epiregulin (ER), amphiregulin (AR), neuregulin
(NRG) subfamily and betacellulin (BTC) [7]. The activation
of EGFR can initiate the downstream signaling cascades, e.g.
the Ras/mitogen-activated protein kinase (MAPK) and
phosphoinositide-3 kinase (PI3K)/Akt [8-11].
BTC is a member of EGF family and acts as a potent
mitogen for cell types, with the higher affinity and specifi-
city for ErbB1/EGFR and ErbB4. Homologous or heterol-
ogous dimers of ErbB family receptor are then formed to
activate signal transduction pathways, such as PI3K/
PDK1/Akt and RAS/RAF/MEK/Erk, leading to a series
of biological effects [12,13]. Abnormal phosphorylation
of Akt and Erk1/2 was considered as an important fac-
tor in the prognosis of cancer [14] and constitutive acti-
vation of EGFR–Akt–mTOR was found in about 18% of
NSCLCs [15].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tients with acute exacerbations of chronic obstructive pul-
monary disease (AECOPD) by integrating inflammatory
mediators with clinical informatics demonstrated that BTC
played an important role in the occurrence of AECOPD
and was associated with the disease severities [16]. We also
found that EGFR–PI3K–Akt–Erk pathway was involved in
the development of lung cancer inflammatory microenvir-
onment by the hyper-production of CXCL8 [17], respon-
sible for leukocyte recruitment, cancer proliferation, and
angiogenesis [18]. The present study further aimed at
understanding the potential association and interaction
mechanisms between BTC and CXCL8 in the inflammatoryFigure 1 LPS induces increased production of BTC and IL-8 in human
left untreated (control) or treated with LPS (0.01, 0.1 and 1 μg/ml) for 4 h. T
followed by qPCR to detect BTC (A) and IL-8 (C) mRNA, as described in Ma
(1 × 105/ml) were stimulated with LPS for 24 h, then the cytokines including B
ELISA. Each data point represents mean ± SEM of three experiments. * and **microenvironment, exploring the expression and biological
function of BTC gene and protein and its receptors in hu-
man lung cancer cells, and define the role of BTC in the
regulation of CXCL8 expression and production in lung
cancer. The present study furthermore investigated the in-
volvement of EGFR–PI3K–Akt–Erk activation in CXCL8
production induced by BTC with consequences on lung
cancer cell proliferation and movement.
Materials and methods
Cell lines and reagents
Human lung cancer cell line A549 cells were cultured in
RPMI 1640 supplemented with penicillin (100 U/ml),lung cancer cells A549. A549 cells grown in complete medium were
otal RNA was extracted and subjected to reverse transcription
terial and Methods. Data were normalized to control. A549 cells
TC (B) and IL-8 (D) in cell-free supernatants were assayed using sandwich
stand for P -values less than 0.05 and 0.01, as compared to control.
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bovine serum (FBS). Human recombinant BTC, Enzyme-
Linked Immunosorbent Assay (ELISA) kits for CXCL8,
anti-human BTC neutralizing antibody were purchased
from R&D Systems (Shanghai, China). PI3K/mTOR in-
hibitors (BEZ235, GDC0941, SHBM1009) and Erk1/2
inhibitor (PD98059) were purchased from Biovision
(California, USA). EGFR inhibitor (Erlotinib) was from
Roche (Basel, Switzerland). EGFR, ErbB2, ErbB3 and
ErbB4 antibodies for immunofluorescent staining were
purchased from Abcam (Hong Kong, China). Cell-IQ
live cell imaging platform was manufactured by Chip-
mantech (Tampere, Finland) and equipped in Center forFigure 2 LPS-induced IL-8 production is BTC dependent in human lun
neutralizing antibody (Neu-Ab) for 2 h. Subsequently, cells were stimula
subjected to reverse transcription followed by qPCR to detect IL-8 mRNA
assayed using sandwich ELISA (B). A549 cells were then stimulated with
to detect its secretion of IL-8 in supernatants (D). Each data point repres
less than 0.05 and 0.01, in comparison with untreated control cells, and
LPS (1 μg/ml) and DMSO, respectively.Biomedical Research, Zhongshan Hospital, Fudan Uni-
versity, Shanghai, China.
Measurement of gene expression
Total RNA was isolated using a guanidinium isothiocyan-
ate/chloroform based technique (TRIZOL, Invitrogen,
USA) and measured with OD 260 nm. RNA was subse-
quently reversed and transcribed to cDNA with the Super-
Script First-strand Synthesis System (Invitrogen, USA).
Quantitative RT-PCR was carried out using an ABI 7000
PCR instrument (Eppendorf, Hamburg, Germany) with the
two-stage program parameters, as follows: 1 min at 95°C,
and then 40 cycles of 5 s at 95°C and 30s at 60°C. Theg cancer cells A549. A549 cells were pretreated with anti-BTC
ted with LPS (1 μg/ml) for 4 h. Total RNA was extracted and
(A). IL-8 in cell-free supernatants after 24 h stimulated by LPS were
BTC (0.01, 0.1 and 1 μg/ml) for 4 h to detect IL-8 mRNA (C) or 24 h
ents mean ± SEM of three experiments. * and ** stand for P- values
+ and ++ stand for P -values less than 0.05 and 0.01, as compared to
Figure 3 Expression of ErbB family receptors in A549 human lung tumor cell line. A549 cell line is positive for EGFR (red labeling) (A), and
ErbB2 (green) (B) and negative for ErbB3 (C) and ErbB4 (D) (FITC staining, green), respectively, in immunofluorescence analysis. DAPI staining
(blue) indicates the localization of nuclei. One representative image from three independent experiments is presented.
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lows: BTC, 5′-TGAAACTAATGGCCTCCTCTGT -3′ (for-
ward [F]) and 5′-CTTTTACGACGTTTCCGAAGAG -3′
(reverse [R]); CXCL8, 5′-TTGCCAAGGAGTGCTAAAG
AA -3′ (F) and 5′-GCCCTCTTCAAAAACTTCTCC -3′
(R); and for human glyceraldehyde-3-phosphate dehydro-
genase (GAPDH), 5′-CCACCCATGGCAAATTCCATGG
CA-3′ (F) and 5′-TCTACACGGCAGGTCAGGTCC
ACC-3′ (R). Specificity of the produced amplification
product was confirmed by examination of dissociation re-
action plots. Each sample was tested in triplicate with
quantitative RT-PCR, and each group had six wells.
Production of BTC and CXCL8
A549 cells were cultured in 24 well cell culture micro-
plates at 1 × 105 cells/well for 24 h and then treated
with lipopolysaccharide (LPS) (Escherichia coli, 055:
B5, Sigma, St. Louis, MO) at concentrations of 0.01,
0.1, and 1 μg/ml for an additional 24 h, respectively, to
study LPS-induced productions of BTC or CXCL8. Cells
were pre-incubated with an anti-human BTC neutralizing
antibody at concentrations of 1, 10, 100 ng/ml or IgG as
non-specific control 2 h before LPS stimulation to studythe role of BTC in LPS-induced CXCL8 production.
Cells were treated with BTC at 0.1 μg/ml or vehicle
and pretreated with BEZ235, GDC0941, SHBM1009,
Erlotinib, or PD98059 at 0.1, 1, or 10 μM, respectively,
for 24 h to investigate the involvement of various sig-
nal pathways. Each experiment was done in six repli-
cate wells for each drug concentration and each time
point. Levels of BTC and CXCL8 proteins in super-
natant were measured by ELISA at the absorbanceof
450 nm.Expression of receptors
A549 were fixed with 4% paraformaldehyde, washed
thrice, permeabilized with 0.1% Triton X-100, and
blocked with 10% goat serum. Cells were incubated
overnight with mouse monoclonal antibodies against
EGFR, ErbB2, ErbB3, or ErbB4, respectively, and then
strained with FITC conjugated anti mouse IgG antibody
(Abcam, HK, China, 1:100). The counterstaining was
performed with DAPI (4, 6′-diamidino-2-phenylindole)
and cells were examined under immunofluorescence
microscope (Olympus/BX51, Tokyo, Japan).
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Apoptosis was analyzed by FACS as previously described
[19]. Lung cancer cells A549 (1 × 106 cell/ml) were
treated with TNF-α at 20 ng/ml/CHX at 2.5 μmol/l
(Sigma, St. Louis, MO) for 24 h in the presence or ab-
sence of BTC at 0.01, 0.1, 1 μg/ml, respectively. Cells
were then harvested and washed thrice, resuspended in
pre-diluted binding buffer, and stained with Annexin V-
FITC (Sigma, St. Louis, MO) for 20 min. Cell apoptosis
was analyzed by flow cytometry (BD Bioscience, San
Diego,CA,USA) using Cell Quest Software (Biomedika,
Canada).Measurements of cell bio-behaviors
The cell bio-behaviors including total cell number,
cell differentiation, and cell movement were mea-
sured by the real-time cell monitoring system, using
a Cell-IQ cell culturing platform (Chip-Man Tech-
nologies, Tampere, Finland), equipped with a phase-
contrast microscope (Nikon CFI Achromat phase
contrast objective with 10x magnification) and a cam-
era (Nikon, Japan). The equipment was controlled by
Imagen software (Chip-Man Technologies). ImagesFigure 4 Treatment with PI3K inhibitors, Erk1/2 inhibitor or Erlotinib
cancer cells. IL-8 production from cells was measured 24 h after the cultu
GDC0941 (GDC; B), SHBM1009 (SHBM; C) or Erlotinib (TKI; D), PD98059 (PD;
0.05 and 0.01 as compared to cells only with DMSO, and + and ++ stand fo
respectively. Data is presented as mean ± SEM and each group has six meawere captured at 5 min intervals for 72 h. Analysis
was carried out with a freely distributed Image soft-
ware (Cell-IQ Imagen v2.9.5c, McMaster Biophotonics
Facility, Hamilton, ON), using the Manual Tracking
plug-in created by Fabrice Cordelieres (Institut Curie,
Orsay, France). Cell-IQ system uses machine vision
technology to monitor and record time-lapse data,
and it can also analyze and quantify cell functions
and morphological parameters. The movement of
each individual cell was measured in the image field
by metering the distance of cell movement.Statistical analysis
Data were represented as mean ± SEM. Statistical sig-
nificance was compared between groups by the Stu-
dent’s t-test, after ANOVA analyses. Increased rates of
total cell number and differentiation were calculated as
the following: Rate (%) = (value at each time point-
value of primary seeding cells)/value of primary seed-
ing cells × 100. Cell movement was calculated as the
mean of the distance of every cell moving between two
images (5 min interval). p-Values less than 0.05 was
considered to be significant.significantly inhibited BTC-induced IL-8 production in A549 lung
re with DMSO alone, BTC at 0.1ug/ml plus DMSO, BEZ235 (BEZ; A),
E) at doses of 0.1, 1.0 or 10 μM. * and ** stand for P- values less than
r P-values less than 0.05 and 0.01, as compared to BTC and DMSO,
surements.
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The mRNA expression and protein production of BTC
in A549 cells significantly increased at the stimulation of
LPS at 1 μg/ml, while those of CXCL8 significantly in-
creased at both 0.1 and 1 μg/ml with a dose-dependent
parttern, as shown in Figure 1 (p < 0.05 or 0.01, respect-
ively). A positive correlation of BTC and CXCL8 expres-
sion in lung cancer was observed. Cells were pretreated
with anti-human BTC neutralizing antibody to investigate
the potential role of endogenous BTC in LPS-induced
over-expression and over-production of CXCL8 mRNA
and proteins. Pretreatment with BTC neutralizing anti-
bodies at concentrations of 10 and 100 ng/ml could sig-
nificantly prevent from LPS-induced over-expression of
CXCL8 mRNA and over-production of CXCL8 proteins,
as compared with those pretreated with vehicle and chal-
lenged with LPS (p < 0.05 or 0.01, respectively, in Figure 2A
and B). The stimulation of exogenous BTC proteins from
the dose of 0.01 μg/ml and on significantly increased the
expression and production of CXCL8 mRNA and proteinsFigure 5 The increased percentage of the total number of lung cance
Monitoring System, at 72 h. The percentage of total number of cells sign
average of total cells values treated with vehicle (DMSO) alone (●), while c
or PD98059 (E) showed a lower increase in the percentage of total numbe
as mean ± SEM and each group has 6–12 measurements.(p < 0.05 or 0.01 in Figure 2C and D), as compared with
those stimulated with vehicle.
Figure 3 demonstrated the expression of ErbB1/EGFR,
ErbB2, ErbB3, or ErbB4 on A549 cells evaluated by im-
munofluorescence staining. We found that A549 cells
constitutively expressed EGFR (Figure 3A) and ErbB2
(Figure 3B), rather than ErbB3 (Figure 3C) and ErbB4
(Figure 3D), of which the expression of EGFR increased
24 hours after the stimulation of exogenous BTC. Our
pilot study demonstrated that BTC at 0.1 μg/ml could sig-
nificantly increase production of CXCL8 A549 cells from
12 h and on, which maintained till at 48 h. Treatments
with PI3K inhibitors (BEZ235, GDC0941 and SHBM1009)
at 1 μM, 10 μM and Erk1/2 inhibitor (PD98059) at 10 μM
significantly inhibited BTC-induced CXCL8 production,
as compared to cells treated with vehicle (P < 0.05 or
0.01, respectively, Figure 4A-E). Treatment with Erloti-
nib (TKI) at all concentrations significantly prevented
BTC-stimulated over-production of CXCL8 (P < 0.01,
Figure 4D).r cells (A549 cells) was assessed using Cell-IQ Alive Image
ificantly increased (∎) after the stimulation with BTC, compared to the
ells treated with BEZ235 (A), GDC0941 (B), SHBM1009 (C), Erlotinib (D)
r of cells, at doses of 0.1, 1 or 10 μM, respectively. Data were presented
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creased after the stimulation of BTC at 0.1 μg/ml, as
compared to those stimulated with vehicle ( P < 0.05 or
0.01, respectively, Figure 5), which was significantly
inhibited by BEZ235 (Figure 5A), GDC0941 (Figure 5B),
SHBM1009 (Figure 5C), Erlotinib (Figure 5D) or PD98059
(Figure 5E) at various concentrations. Of them inhibi-
tory effects of PI3K inhibitors (BEZ235, GDC0941 and
SHBM1009) showed a dose-dependent pattern. Inhibi-
tors also significantly inhibited BTC-increased percent-
ages of differentiated cells, as shown in Figure 6A–E.
Figure 7A–E demonstrated similar inhibitory effects of
inhibitors on the BTC-increased cell movements, as
compared to BTC stimulation alone (P < 0.05 or 0.01,
respectively). The number of apoptotic cells signifi-
cantly increased in cells pretreated with vehicle and
stimulated with TNF-α/CHX for 24 h, as compared with
those pretreated with vehicle or BTC without the stimu-
lation (p < 0.01, respectively, Figure 8). Cells pretreated
with different doses of exogenous BTC developed into
apoptosis less than those pretreated with vehicle after
the stimulation with TNF-α/CHX.Figure 6 The percentage of the differentiated lung cancer cells (A549
at 72 h. The percentage of differentiated cells significantly increased (∎) af
values treated with vehicle (DMSO) alone (●), while cells treated with BEZ2
showed a lower increase, or even a decrease in the percentage of differen
presented as mean ± SEM and each group has 6–12 measurements.Discussion
BTC is expressed in bronchial mucosa and lung tissue
cells, e.g. the alveolar and airway epitheliums, fibroblasts,
and macrophages [8,20]. The evidence from our previ-
ous studies and others suggested that BTC play a critical
role in the development of lung inflammation through
the regulation of the cytokine secretion pattern and
tumor cell progression through EGFR ligation, possibly
associated with the over-production of CXCL8 [21-25].
The activation of the EGFR pathway could contribute to
the over-expression of CXCL8 in human bronchial epi-
thelial cells by multi-stimuli, e.g. HB-EGF [26], MMP-12
[27]. We found that EGF was involved in the develop-
ment of the lung cancer inflammatory microenviron-
ment through the over-production of CXCL8 associated
with the activation of EGFR pathway [17]. The present
study provided the further evidence that both BTC and
CXCL8 could be over-produced directly by lung cancer
cell per se in the inflammatory condition and/or stimuli
like LPS.
Our data indicated that lung cancer cells per se may act
as a primary receptor to be stimulated and challenged bycells) was assessed using Cell-IQ Alive Image Monitoring System,
ter the stimulation with BTC, compared to the average of total cells
35 (A), GDC0941 (B), SHBM1009 (C), Erlotinib (D) or PD98059 (E)
tiated cells, at doses of 0.1, 1 or 10 μM, respectively. Data were
Figure 7 The percentage of lung cancer cells (A549 cells) movement was assessed using Cell-IQ Alive Image Monitoring System, at
72 h. The percentage of A549 cells movement significantly increased (∎) after the stimulation with BTC, compared to the average of total cells
values treated with vehicle (DMSO) alone (●), while cells treated with BEZ235 (A), GDC0941 (B), SHBM1009 (C), Erlotinib (D) or PD98059 (E)
showed a lower increase, or even a decrease in the percentage of A549 cells movement, at doses of 0.1, 1 or 10 μM, respectively. Data were
presented as mean ± SEM and each group has 6–12 measurements.
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duce the mediators and accelerate the development of the
local inflammatory microenvironment. The present study
also evidenced that the potential mechanism by which
lung cancer cells are regulated to produce chemoattractive
factors could be that BTC produced by a lung cancer cell
per se or by other neighbor cells might regulate the over-
production of secondary inflammatory factors like CXCL8
through EGFR–PI3K–Akt–Erk pathway.
Many regulatory factors may contribute to the mo-
lecular mechanism by which LPS can stimulate lung
cancer cells to produce inflammatory mediators. Re-
sults from the present study demonstrated that both
endogenous and exogenous BTC could induce the
over-production of CXCL8. The finding that levels of
CXCL8 in cells blocked with anti-BTC neutralizing
antibody and challenged with LPS were still signifi-
cantly higher than those without LPS indicates the ex-
istence of biological efforts from other factors, like EGF
[17]. We found that the signal pathway of BTC-EGFR-
PI3K axis may play the crucial and dependent role inthe mechanism of CXCL8 production of lung cancer
cells, evidenced by the finding that the over-production
of CXCL8 by BTC was fully prevented by PI3K and
EGFR inhibitors. It implies that the BTC-EGFR-PI3K-
CXCL8 chain can be the potential of new anti-
inflammatory therapeutic target in lung cancer or
chronic lung diseases.
The EGFR-dominated signal pathway, e.g. PI3K,
Erk1/2 and STAT, are related to CXCL8 expression in
airway epithelium cells [28,29]. We provided direct
evidence that A549 cells constitutively expressed EGFR
and ErbB2, while the expression of EGFR increased
after BTC stimulation in human lung cancer cells. PI3K
inhibitors (BEZ235, GDC0941 and SHBM1009) and Erk1/
2 inhibitor PD98059 could inhibit over-production of
CXCL8 initiated by the over activation of BTC-EGFR
pathway.
The PI3K activation has been recently found to play
the important role in the development of acute and
chronic lung inflammation and injury [30]. PI3K/Akt
and Erk1/2 pathways could play the decisive role in
Figure 8 BTC pretreatment induces resistance of human lung cancer cells to apoptosis induction by TNF-α/CHX. A549 cells (1 × 106/ml)
were pretreated with BTC for 4 h, then stimulated with 20 ng/ml TNF-α/CHX for 24 h. The cells were stained with annexin V and PI and subjected
to FACS assay of cellular apoptosis. ** stand for P- value less than 0.01 as compared to control (DMSO only), and ++ stand for P-value less than
0.01, as compared to BTC + DMSO. Data were presented as mean ± SEM of three independent experiments.
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while the inhibition of PI3K/Akt pathway could reduce
the migration and invasion of NSCLC cells [32]. We
found that BTC could increase the proliferation, differenti-
ation and movement of lung cancer cells, which could be
down-regulated by PI3K, Erk, and EGFR inhibitors. The
pretreatment with BTC could increase the resistance of
lung cancer cells against TNF-α/CHX-induced apoptosis
in a dose-associated pattern.Conclusions
In summary, the present study demonstrated that LPS
increased the over-production of BTC and CXCL8
from human lung cancer cells, which could be blocked
by anti-BTC neutralizing antibody. Both endogenous and
exogenous BTC could increase the over-production
CXCL8 through EGFR–PI3K–Akt–Erk pathway activa-
tion. Of EGFRs, EGFR expression increased after the
stimulation of BTC. BTC also increased the proliferation,
Figure 9 Proposed mechanism of BTC-stimulated IL-8 production and bio-behaviors of lung cancer cells. BTC could directly stimulate IL-8
production and bio-behaviors of lung cancer cells through the activation of EGFR, PI3K/Akt, and Erk signal pathway, then lead to the recruitment
of inflammatory cells in the cancer tissue and the formation of inflammatory microenvironment. This has been highlighted as an important factor
responsible for the sensitivity of human lung cancer to therapies and prognosis of patients.
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http://www.translational-medicine.com/content/12/1/70differentiation, and movement of lung cancer cells and
increased cell resistance against apoptosis. It indicates
that lung cancer cells per se contribute to the develop-
ment of the local inflammatory microenvironment,
probably leading to the recruitment of inflammatory
cells in the cancer tissue and the formation of inflam-
matory microenvironment (Figure 9). Thus, our data
indicate that the signal pathway of BTC-EGFR–PI3K–
Akt–Erk-CXCL8 plays an important role in the inflam-
matory microenvironment in lung cancer, as a novel
therapeutic approach to lung cancer.Abbreviations
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